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requiring diabetics were 40.8% of the population studied. ACS was
the presentation in 52.3% patients.
Primary endpoint results will be presented.
Conclusion:TUXEDO is the largest randomized trial of PES vs EES in
subjectswithDMandwill provide additional insights intomanage-
ment of these high risk patients.
Experience with primary percutaneous
coronary interventions in ST elevation
myocardial infarction in tertiary care
hospital
Wasim Rashid *, Dileep Tiwari, Upendra Kaul,
Ashok Seth, Atul Mathur, T.S. Kler,
Praveer Agarwal, Nisith Chandra, Vinay Jetley,
Vishal Rastogi, Vijay Kumar
Fortis Escort Heart Institute, New Delhi, India
Background: Coronary artery disease is currently the most com-
mon, non-infectious disease in India. STEMI is the most cata-
strophic presentation. Primary PCI is the preferred reperfusion
strategy in patients with STEMI presenting within 12 h to an
experienced center. There is paucity of data regarding primary
PCI in ourmilieu. This study is designed to prospectively look at the
various aspects of contemporary practice of primary PCI at a
tertiary care hospital and also to evaluate the 30-day outcomes.
Methods: All patients who present to emergency room as STEMI
within 12 h of symptom onset and give informed consent for
primary PCI as the reperfusion therapy are being enrolled for this
study. The detailed demographic data is being collected system-
atically. In addition the ECG and echocardiographic ﬁndings the
angiographic ﬁndings and procedural details are reviewed by an
independent investigator. Procedural success is deﬁned as
achievement of vessel patency to a residual stenosis <30%. The
patients are being followed during their in-hospital stay for any
acute complications and at 30 days for occurrence ofmajor adverse
cardiac events (all cause mortality, acute and sub acute stent
thrombosis as per ARC deﬁnition, target lesion revascularization,
and major bleeding as per BARC criteria). The 30 day follow up
results are being recorded.
Results: In this ongoing study 56 patients, 51(89.7%) males, mean
age 59.3 years. 46 (81.4%) patients presented as Killip class I, 6
(11.1%) as Killip class II and 2 (3.7%) as Killip III and IV each. 32
(58.6%) patients had inferior while 21 (38.2%) had anterior wall MI
at presentation. The mean time to hospital arrival from symptom
onset was 3.4 h and mean door to balloon time was 59.9 min. On
angiography 20 (37.03%) had single vessel disease while 22 (40.7%)
and 10 (18.5%) had double and triple vessel disease respectively. All
patients were loaded with aspirin 325 mg. The second antiplatelet
agent was the clopidogrel in 16.6% cases and ticagrelor in 66.6%
cases, given in emergency room, while prasugrel was given in
16.6% cases in cath lab after conﬁrmation of coronary anatomy.
Heparin alone was used in 12 (21.4%) cases, bivalirudin in 6 (10.7%)
and heparin + GpIIb/IIIa inhibitors were used in 38 (67.8%) patients
and the most common agent being abciximab (61.6% cases).
Thrombus aspiration was done in 27 (48.1%) patients. All patients
were treated with DES except one patient in which bioresorbable
scaffold (Absorb) was deployed. Culprit vessel revascularization
was the default strategy in majority (81%). In 5 cases multivessel
revascularization was done, out of which it was done during the
index procedure in 3 patients and as a staged procedure in 2
patients. There was one in-hospital death due to no reﬂow phe-
nomenon during index procedure. At 30 days 2 patients died, one
with sepsis and multiorgan failure and other had sudden death at
home without establishing the cause and included as probable
stent thrombosis. Bleeding complications included BARC subtype 1
in 13%, and type 2 in 3.4% patients. No major bleeding, BARC
subtype 3, was recorded at 30 days follow up. All the bleeding
complications were occurred in those patients, who received
heparin + Gp IIb/IIIa inhibitor.
Conclusions:This ongoing study throws light on important aspects
of the clinical and procedural proﬁle of patients presenting with
STEMIwho are undergoing primary PCI. Data of 100 patientswill be
presented.
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Background: Cardiovascular diseases (CAD) are the leading cause
of morbidity and mortality in patients of CKD and they begin well
before the onset of dialysis. Optimal approach of revascularization
in patients with kidney disease has not been determined.With the
availability of drug eluting stents & DAP, the scenario has changed.
The objective of study was to see disease pattern, immediate and
short term outcome of CAD in patients having CKD, with PCI.
Methods: We included 305 patients of CKD (with creatinine clear-
ance <60 ml/min/1.73 m2 having CAD, who underwent PCI with
DES (study group) and compared with similar number of age and
sex matched controls with creatinine clearance ≥60 ml/min/
1.73 m2, having CAD who underwent PCI with DES (control group).
The clinical and angiographic follow-up data before and after PCI
was collected at 1 month, 6 months and 12 months, using a
standard questionnaire. Data about amount of dye used, type of
dye used, renal outcomes at discharge, type of antiplatelet used,
beta blockers, ACE inhibitors/ARB, statins used & Duration of stay
in hospital was collected. Using amultiple logistic regressionmode
multivariable analysis was performed.
Results: The base line variables were similar in the 2 groups. There
was a gradual increase of prevalence of HTN as creatinine clear-
ance falls. More number of patients in study group had diabetes as
compared to control group but the difference between two groups
was not statistically signiﬁcant. There was no signiﬁcant differ-
ence between two groups regarding smoking and dyslipidemia.
Height was not signiﬁcantly different between two groups; how-
ever weight & BMI was signiﬁcantly lower in study group. Ejection
fraction was signiﬁcantly lower in study group as compared to
control group ( p < .001). Mean ejection fraction was 47.39% in
study group; it was 51.67% in control group. Hemoglobin, BUN,
serum creatinine & mean eGFR were signiﬁcantly lower in study
group. To estimate creatinine clearance EPI-CKD equation was
used.
Unstable angina as indication for PCI was signiﬁcantly more in
study group. In study group more patients had triple vessel dis-
ease, more lesions was of diffuse & calciﬁed type ( p < .001). Type B
lesionsweremore in control group and type C lesionsweremore in
study group ( p < .001). Angiotensin converting enzyme inhibitors
or angiotensin receptor blockers were used less in study group as
compared to control group. Amount of dye used during PCI was
higher in control group. Iodixanol (iso-osmolar) was used more in
study group. More number of patients in study group developed
contrast induced nephropathy. Rate of complete revascularization
achieved was also less in lower creatinine clearance group
( p < .001). Average number of days stayed in hospital was signiﬁ-
cantly more in study group ( p < .001). Peri-procedural MI occurred
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in more number of patients in study group ( p = .003). From one
month to sixmonth signiﬁcantlymore number of patients in study
group hadMI and repeat revascularization. Total number of death,
myocardial infarction and repeat revascularization at one yearwas
signiﬁcantly more in study group as compared to control group.
Statistically higher number of patients in study group had com-
bined MACCE at one year as compared to control group (<.001).
Conclusions: During and after PCI decreased creatinine clearance
is independently associated with death and major adverse events.
It is a powerful predictor of in-hospital myocardial infarction and
1-year ischemic events including death, MI and repeat revascular-
ization renal dysfunction patients.
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Background: Coronary artery disease (CAD) continues to be the
main cause of death worldwide. Data available from clinical trials
or registries does not adequately represent populations with stable
CAD. It is important to have longitudinal observations of a repre-
sentative large cohort of patients with stable CAD, spanning sev-
eral geographic regions, focusing on stable outpatients (as opposed
to patients hospitalized or recently discharged from hospitals for
acute manifestations of the disease), and including both sympto-
matic and asymptomatic patients.
Method: CLARIFY (The prospeCtive observational LongitudinAl
RegIstry oF patients with stable coronary arterY disease) is an
international, prospective, observational, longitudinal registry of
outpatientswith stable CAD, deﬁned as priormyocardial infarction
or revascularization procedure, evidence of coronary stenosis of
>50%, or chest pain associated with proven myocardial ischemia.
A total of 33,438 patients were enrolled from 45 countries in Africa,
Asia, Australia, Europe, the Middle East, and North, Central and
South America. 809 patients were recruited from India, with repre-
sentation from various cities. The data was collected at baseline
and annually for 5 years to ascertain clinical events, hospitaliza-
tion etc.
Results: Indian population differed from the global population in
terms of having more patients with history of diabetes (44.3% vs.
28.73%) and average heart rate (76.6 bpm vs. 68.3 bpm) at baseline.
The 2 years outcomes data is in table
Outcome Level n with event/n
ill group (%)
HR (95% CI) p-Value
All cause death 1: Total CLARIFY population (excluding India) 952/31,693 (3.0%) 1.00 (–) 0.3930
2: India 28/805 (3.5%) 1.18 (0.81. 1.72)
Cardiovascular death 1: Total CLARIFY population (excluding India) 458/31,692 (1.4%) 1.00 (–) 0.8715
2: India 12/805 (1.5%) 1.05 (0.59. 1.86)
Non-cardiovascular death 1: Total CLARIFY population (excluding India) 308/31,692 (1.0%) 1.00 (–) 0.4048
2: India 10/805 (1.2%) 1.31 (0.7, 2.45)
Unknown cause of death 1: Total CLARIFY population (excluding India) 186/31,693 (0.6%) 1.00 (–) 0.5404
2: India 6/805 (0.7%) 1.29 (0.57. 2.91)
Myocardial infarction
(fatal or non-fatal)
1: Total CLARIFY population (excluding India) 543/31,689 (1.7%) 1.00 (–) 0.0256
2: India 5/805 (0.6%) 0.37 (0.15,0.88)
Stroke (fatal or non-fatal) 1: Total CLARIFY population (excluding India) 296/31,689 (0.9%) 1.00 (–) 0.8738
2: India 7/805 (0.9%) 0.94(0.45. 1.99)
Cardiovascular death or non-fatal MI 1: Total CLARIFY population (excluding India) 830/31,689 (2.6%) 1.00 (–) 0.0903
2: India 13/805 (1.6%) 0.62 (0.36. 1.08)
Cardiovascular death.
Non-fatal MI or non-fatal stroke
1: Total CLARIFY population (excluding India) 1049/31,689 (3.3%) 1.00 (–) 0.0458
2: India 16/805 (2.0%) 0.6 (0.37. 0.99)
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